医学
电流(流体)
炎症性肠病
疾病
重症监护医学
疾病管理
内科学
胃肠病学
工程类
帕金森病
电气工程
作者
Gerhard Rogler,Abha G. Singh,Arthur Kavanaugh,David T. Rubin
出处
期刊:Gastroenterology
[Elsevier BV]
日期:2021-08-03
卷期号:161 (4): 1118-1132
被引量:535
标识
DOI:10.1053/j.gastro.2021.07.042
摘要
Inflammatory bowel diseases (IBDs) are systemic diseases that manifest not only in the gut and gastrointestinal tract, but also in the extraintestinal organs in many patients. The quality of life for patients with IBD can be substantially affected by these extraintestinal manifestations (EIMs). It is important to have knowledge of the prevalence, pathophysiology, and clinical presentation of EIMs in order to adapt therapeutic options to cover all aspects of IBD. EIMs can occur in up to 24% of patients with IBD before the onset of intestinal symptoms, and need to be recognized to initiate appropriate diagnostic procedures. EIMs most frequently affect joints, skin, or eyes, but can also affect other organs, such as the liver, lung, and pancreas. It is a frequent misconception that a successful therapy of the intestinal inflammation will be sufficient to treat EIMs satisfactorily in most patients with IBD. In general, peripheral arthritis, oral aphthous ulcers, episcleritis, or erythema nodosum can be associated with active intestinal inflammation and can improve on standard treatment of the intestinal inflammation. However, anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis usually occur independent of disease flares. This review provides a comprehensive overview of epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in IBD.
科研通智能强力驱动
Strongly Powered by AbleSci AI